Clinical Trials
859 trialsNCT04633252 2026-05-27
A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05562830 2026-05-27
MK-3475-04A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT05710848 2026-05-27
A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
SURGE Therapeutics
Phase 1/2 Recruiting
NCT07288359 2026-05-27
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
Phase 1/2 Recruiting
NCT06353386 2026-05-26
MK-5684-01A
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT06574880 2026-05-26
STARLiT
Case Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT07049926 2026-05-26
MK-3475-03C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07293351 2026-05-26
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT03172754 2026-05-22
Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Fox Chase Cancer Center
Phase 1/2 Active not recruiting
NCT05287945 2026-05-22
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
Oncorena AB
Phase 1/2 Recruiting
NCT05682443 2026-05-22
PRESERVE-006
OncoC4, Inc.
Phase 1/2 Active not recruiting
NCT07227415 2026-05-22
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Pfizer
Phase 1/2 Recruiting
NCT07529717 2026-05-22
CRIUS-1
AstraZeneca
Phase 1/2 Recruiting
NCT03317392 2026-05-20
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04037254 2026-05-20
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
Phase 1/2 Completed
NCT06814496 2026-05-20
RABBIT
University of Arizona
Phase 1/2 Recruiting
NCT07407582 2026-05-20
Ph. I/II Sodium Thiosulfate for OtoProtection During Cisplatin (STOP-CIS)
University of Arizona
Phase 1/2 Recruiting
NCT00458536 2026-05-19
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT04901702 2026-05-19
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
NCT04626479 2026-05-18
MK-3475-03A
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT05267626 2026-05-18
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Aulos Bioscience, Inc.
Phase 1/2 Recruiting
NCT07594106 2026-05-18
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Not yet recruiting
NCT03437941 2026-05-15
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics
Phase 1/2 Terminated
NCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT04977453 2026-05-15
Keynote B59
GI Innovation, Inc.
Phase 1/2 Recruiting
NCT06863272 2026-05-15
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07564102 2026-05-15
dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy
Mochida Medical USA, Inc.
Phase 1/2 Not yet recruiting
NCT07590934 2026-05-15
PROSPECTOR
AstraZeneca
Phase 1/2 Not yet recruiting
NCT05413850 2026-05-14
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Phase 1/2 Recruiting
NCT07285694 2026-05-14
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Arsenal Biosciences, Inc.
Phase 1/2 Recruiting
NCT07579195 2026-05-14
Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
University of Washington
Phase 1/2 Not yet recruiting
NCT03854474 2026-05-13
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT04071236 2026-05-13
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT05036226 2026-05-13
COAST
Medical University of South Carolina
Phase 1/2 Recruiting
NCT04902872 2026-05-12
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Cybrexa Therapeutics
Phase 1/2 Completed
NCT05919264 2026-05-12
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT01171898 2026-05-11
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)
Aragon Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT04152499 2026-05-11
MK-2870-001
Klus Pharma Inc.
Phase 1/2 Active not recruiting
NCT05661955 2026-05-11
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
BeOne Medicines
Phase 1/2 Active not recruiting
NCT07226986 2026-05-11
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting
NCT04145375 2026-05-08
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Zenith Epigenetics
Phase 1/2 Enrolling by invitation
NCT05316155 2026-05-08
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Janssen Research & Development, LLC
Phase 1/2 Recruiting
NCT07181161 2026-05-08
SEACLIFF
AstraZeneca
Phase 1/2 Recruiting
NCT07206056 2026-05-08
TulmiSTAR-01
Novartis
Phase 1/2 Recruiting
NCT07414940 2026-05-08
ACT-RESoLUTE
University College, London
Phase 1/2 Recruiting
NCT07192614 2026-05-07
ACTIVATED-4-PC
AstraZeneca
Phase 1/2 Recruiting
NCT02535533 2026-05-06
SLM + Axitinib for Clear Cell RCC
University of Iowa
Phase 1/2 Completed
NCT04626518 2026-05-06
KEYMAKER-U03
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
NCT04868604 2026-05-06
SECuRE
Clarity Pharmaceuticals Ltd
Phase 1/2 Recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting